EMBO Molecular Medicine (Jun 2024)

Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients

  • Laura de Boni,
  • Amber Wallis,
  • Aurelia Hays Watson,
  • Alejandro Ruiz-Riquelme,
  • Louise-Ann Leyland,
  • Thomas Bourinaris,
  • Naomi Hannaway,
  • Ullrich Wüllner,
  • Oliver Peters,
  • Josef Priller,
  • Björn H Falkenburger,
  • Jens Wiltfang,
  • Mathias Bähr,
  • Inga Zerr,
  • Katharina Bürger,
  • Robert Perneczky,
  • Stefan Teipel,
  • Matthias Löhle,
  • Wiebke Hermann,
  • Björn-Hendrik Schott,
  • Kathrin Brockmann,
  • Annika Spottke,
  • Katrin Haustein,
  • Peter Breuer,
  • Henry Houlden,
  • Rimona S Weil,
  • Tim Bartels

DOI
https://doi.org/10.1038/s44321-024-00083-5
Journal volume & issue
Vol. 16, no. 7
pp. 1657 – 1674

Abstract

Read online

Abstract Synucleinopathies such as Parkinson’s disease (PD) are defined by the accumulation and aggregation of the α-synuclein protein in neurons, glia and other tissues. We have previously shown that destabilization of α-synuclein tetramers is associated with familial PD due to SNCA mutations and demonstrated brain-region specific alterations of α-synuclein multimers in sporadic PD patients following the classical Braak spreading theory. In this study, we assessed relative levels of disordered and higher-ordered multimeric forms of cytosolic α-synuclein in blood from familial PD with G51D mutations and sporadic PD patients. We used an adapted in vitro-cross-linking protocol for human EDTA-whole blood. The relative levels of higher-ordered α-synuclein tetramers were diminished in blood from familial PD and sporadic PD patients compared to controls. Interestingly, the relative amount of α-synuclein tetramers was already decreased in asymptomatic G51D carriers, supporting the hypothesis that α-synuclein multimer destabilization precedes the development of clinical PD. Our data, therefore suggest that measuring α-synuclein tetramers in blood may have potential as a facile biomarker assay for early detection and quantitative tracking of PD progression.

Keywords